Reimagining Medicine Q2 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
KisqaliⓇ continued strong momentum globally, with increasing
recognition of its differentiated profile
GROWTH
Sales evolution
USD m, % cc
Ex-US
US
+66%
493
308
269
US MBC NBRx share1
Rolling 3 months, %
198
15%
224
110
Q2 2022
Q2 2023
May 2022
Consistent efficacy
KISQALI
Kisqali Ph3 OS results in 1L mBC2
34%
Stage IV
HR
95% CI
MONALEESA-2
0.76
(0.63, 0.93)
MONALEESA-7 0.76
(0.61, 0.96)
May 2023
MONALEESA-3 0.67 (0.50, 0.90)
Consistent benefit regardless of combination
endocrine therapy, menopausal status, or site
and number of metastases
Included in NCCN guidelines³ as the only
Category 1 treatment for 1L mBC with Al
1. Of CDK4/6 mBC market, US 3 months ending May 2023 from IQVIA Breast Cancer
mBC metastatic breast cancer. NBRX-new to brand prescription. NCCN - national comprehensive cancer network. Al aromatase inhibitor.
Market Sizing report. 2. MONALEESA-2: Hortobagyi et al, NEJM 2022; MONALEESA-7: Lu et al, Clin Cancer Res 2022; MONALEESA-3: Neven et al, ESMO Breast 2022. 3. NCCN Guidelines updated as of 27-Jan-2023.
Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 48 of Condensed Interim Financial Report.
8 Investor Relations | Q2 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation